2026Q1
| Insider | Role (last 12 mo) | Shares held | Filed at |
|---|---|---|---|
| PharmaCyte Biotech, Inc. | — | 12,711,864 | Nov 28, 2023 |
| Schmieg Martin | — | 425,328 | Mar 30, 2009 |
| Silverman Joshua | CEO | 170,000 | Nov 22, 2023 |
| Farb Daniel Stuart | — | 125,000 | Dec 30, 2022 |
| Allen Daniel | — | 125,000 | Dec 30, 2022 |
| Exec date | Filing date | Insider | Role | Signal | Confidence | Shares | % of shares | Under plan? | Amount (USD) |
|---|---|---|---|---|---|---|---|---|---|
| Jan 5, 2026 | Jan 7, 2026 | Silverman Joshua | CEO | Buy | 95.0 | +100,000 | 27.30% | ✗ | $80.5K |
| Jan 5, 2026 | Jan 7, 2026 | SCHECHTER JONATHAN | Director | Buy | 91.3 | +60,000 | 45.28% | ✗ | $48.2K |
| Dec 12, 2025 | Dec 12, 2025 | WEINSTEIN ROBERT | Director | Sell | 91.3 | +41,250 | 100.00% | ✗ | $34.4K |
| Dec 12, 2025 | Dec 12, 2025 | WALKER WAYNE REMELL | Director | Sell | 91.3 | +20,625 | 100.00% | ✗ | $17.2K |
| Dec 12, 2025 | Dec 12, 2025 | Silverman Joshua | CEO | Sell | 97.5 | +316,250 | 632.50% | ✗ | $263.9K |
| Dec 12, 2025 | Dec 12, 2025 | SCHECHTER JONATHAN | Director | Sell | 95.0 | +82,500 | 165.00% | ✗ | $68.9K |
| Dec 12, 2025 | Dec 12, 2025 | Abecassis Michael M | Director | Sell | 91.3 | +20,625 | 836.04% | ✗ | $17.2K |
| Apr 30, 2024 | Jul 17, 2024 | WEINSTEIN ROBERT | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Apr 30, 2024 | Jul 17, 2024 | WALKER WAYNE REMELL | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Apr 30, 2024 | Jul 17, 2024 | SCHECHTER JONATHAN | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Apr 30, 2024 | Jul 17, 2024 | Abecassis Michael M | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Nov 28, 2023 | PharmaCyte Biotech, Inc. | 10% Owner | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Nov 20, 2023 | Nov 22, 2023 | WEINSTEIN ROBERT | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Nov 20, 2023 | Nov 22, 2023 | WALKER WAYNE REMELL | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Nov 20, 2023 | Nov 22, 2023 | Trujillo Carlos | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Nov 20, 2023 | Nov 22, 2023 | Silverman Joshua | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Nov 20, 2023 | Nov 22, 2023 | SCHECHTER JONATHAN | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Nov 20, 2023 | Nov 22, 2023 | Abecassis Michael M | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Dec 30, 2022 | WALKER WAYNE REMELL | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Dec 28, 2022 | Dec 30, 2022 | Farb Daniel Stuart | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Dec 28, 2022 | Dec 30, 2022 | Allen Daniel | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Nov 16, 2022 | WEINSTEIN ROBERT | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Aug 24, 2022 | Allen Daniel | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Aug 23, 2022 | SCHECHTER JONATHAN | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Aug 23, 2022 | STOVER JACK E | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Aug 23, 2022 | Silverman Joshua | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Aug 23, 2022 | Farb Daniel Stuart | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Apr 11, 2022 | Loehr Matthias | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Sep 3, 2021 | Trujillo Carlos | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Aug 31, 2021 | Waggoner Kenneth L. | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Aug 31, 2021 | YUEN THOMAS C K | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Aug 31, 2021 | Crabtree Gerald W | Chief Science Officer | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Aug 20, 2021 | Liquard Thomas | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Aug 20, 2021 | Tong Raymond CF | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Aug 20, 2021 | Abecassis Michael M | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Mar 30, 2009 | Schmieg Martin | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Mar 30, 2009 | BARNES MARYLEW | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - |